Biogenetics Fund, managed by Widwin Investment Co., Ltd. and an undisclosed buyer agreed to acquire 34.9% stake in Unidus Corporation (KOSDAQ:A044480) from Seong-Hun Kim for KRW 20 billion on November 11, 2017. Under the terms of the deal, Biogenetics Fund will acquire 1.6 million shares and will own 18.31% stake in Unidus Corporation and rest will be acquired by the undisclosed buyer. As per the terms of the transaction, 3 million shares will be acquired at a price of KRW 6667 per share. A deposit of KRW 2 billion has been transferred to the escrow account on November 10, 2017. The remaining payment of KRW 18 billion will be paid 3 business days before the extraordinary shareholders' meeting. The gross consideration including deposit and the remaining transaction consideration will be paid at time of extraordinary shareholders' meeting end. The deal will be funded by own funds. Seong-Hun Kim will retain 0.98% shares equaling 0.084 million shares in Unidus Corporation post transaction closing. Three internal Directors, one external Director, and one auditor will be appointed at the 45th extraordinary meeting of shareholders of Unidus Corporation held on December 27, 2017. The transaction is expected to close on December 27, 2017. Biogenetics Fund, managed by Widwin Investment Co., Ltd. and an undisclosed buyer completed the acquisition of 34.9% stake in Unidus Corporation (KOSDAQ:A044480) from Seong-Hun Kim on December 27, 2017.